[Anticoagulant therapy in venous thromboembolism]

Herz. 2008 Feb;33(1):52-8. doi: 10.1007/s00059-008-3087-3.
[Article in German]

Abstract

Venous thromboembolism (VTE) is a common cause of morbidity and mortality with an estimated annual incidence of 1 : 1,000. Patients show individual risk profiles with regard to recurrent VTE and treatment-associated bleeding, which are characterized by the presence of endogenous factors (such as hereditary thrombophilic disorders), but much more by exogenous factors (underlying disease). This results in risk-adapted therapeutic recommendations, which will be discussed in the following review.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / adverse effects*
  • Hemorrhage / chemically induced*
  • Hemorrhage / prevention & control*
  • Humans
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians'
  • Venous Thromboembolism / complications
  • Venous Thromboembolism / prevention & control*

Substances

  • Fibrinolytic Agents